日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Distinct roles of vaccine-induced SARS-CoV-2-specific neutralizing antibodies and T cells in protection and disease.

疫苗诱导的 SARS-CoV-2 特异性中和抗体和 T 细胞在保护和疾病中发挥着不同的作用

Yan Jingyi, Bangalore Chandrashekar Ravenna, Nikouyan Negin, Appelberg Sofia, Silva Daniela Nacimento, Yao Haidong, Pasetto Anna, Weber Friedemann, Weber Sofie, Larsson Olivia, Höglund Urban, Bogdanovic Gordana, Grabbe Malin, Aleman Soo, Szekely Laszlo, Szakos Attila, Tuvesson Ola, Gidlund Eva-Karin, Cadossi Matteo, Salati Simona, Tegel Hanna, Hober Sophia, Frelin Lars, Mirazimi Ali, Ahlén Gustaf, Sällberg Matti

Novel prime-boost immune-based therapy inhibiting both hepatitis B and D virus infections

一种新型的免疫增强疗法,可同时抑制乙型肝炎病毒和丁型肝炎病毒感染。

Burm, Rani; Maravelia, Panagiota; Ahlen, Gustaf; Ciesek, Sandra; Caro Perez, Noelia; Pasetto, Anna; Urban, Stephan; Van Houtte, Freya; Verhoye, Lieven; Wedemeyer, Heiner; Johansson, Magnus; Frelin, Lars; Sällberg, Matti; Meuleman, Philip

Blocking Entry of Hepatitis B and D Viruses to Hepatocytes as a Novel Immunotherapy for Treating Chronic Infections

阻断乙型和丁型肝炎病毒进入肝细胞作为一种治疗慢性感染的新型免疫疗法

Maravelia, Panagiota; Frelin, Lars; Ni, Yi; Caro Pérez, Noelia; Ahlén, Gustaf; Jagya, Neetu; Verch, Georg; Verhoye, Lieven; Pater, Lena; Johansson, Magnus; Pasetto, Anna; Meuleman, Philip; Urban, Stephan; Sällberg, Matti

SARS-CoV-2-specific humoral and cellular immunity persists through 9 months irrespective of COVID-19 severity at hospitalisation

无论住院时 COVID-19 的严重程度如何,SARS-CoV-2 特异性体液免疫和细胞免疫可持续长达 9 个月。

Sandberg, John Tyler; Varnaitė, Renata; Christ, Wanda; Chen, Puran; Muvva, Jagadeeswara R; Maleki, Kimia T; García, Marina; Dzidic, Majda; Folkesson, Elin; Skagerberg, Magdalena; Ahlén, Gustaf; Frelin, Lars; Sällberg, Matti; Eriksson, Lars I; Rooyackers, Olav; Sönnerborg, Anders; Buggert, Marcus; Björkström, Niklas K; Aleman, Soo; Strålin, Kristoffer; Klingström, Jonas; Ljunggren, Hans-Gustaf; Blom, Kim; Gredmark-Russ, Sara

The SARS-CoV-2 N Protein Is a Good Component in a Vaccine

SARS-CoV-2 N蛋白是疫苗的良好成分

Ahlén, Gustaf; Frelin, Lars; Nikouyan, Negin; Weber, Friedemann; Höglund, Urban; Larsson, Olivia; Westman, Marie; Tuvesson, Ola; Gidlund, Eva-Karin; Cadossi, Matteo; Appelberg, Sofia; Mirazimi, Ali; Sällberg, Matti

Hepatitis C Virus-Specific T Cell Receptor mRNA-Engineered Human T Cells: Impact of Antigen Specificity on Functional Properties

丙型肝炎病毒特异性T细胞受体mRNA工程化人T细胞:抗原特异性对功能特性的影响

Balasiddaiah, Anangi; Davanian, Haleh; Aleman, Soo; Pasetto, Anna; Frelin, Lars; Sällberg, Matti; Lohmann, Volker; Koh, Sarene; Bertoletti, Antonio; Chen, Margaret

Hepatitis C Virus Nonstructural 3/4A Protein Dampens Inflammation and Contributes to Slow Fibrosis Progression during Chronic Fibrosis In Vivo.

丙型肝炎病毒非结构蛋白 3/4A 可抑制炎症并有助于减缓体内慢性纤维化过程中的纤维化进展

Bansal Ruchi, Frelin Lars, Brenndörfer Erwin Daniel, Storm Gert, Prakash Jai, Sällberg Matti

A small step closer to the Holy Grail of DNA vaccines: undisputed clinical benefit in humans

距离DNA疫苗的圣杯又近了一步:在人体中取得无可争议的临床疗效

Frelin, Lars; Sällberg, Matti

The hepatitis C virus non-structural NS5A protein impairs both the innate and adaptive hepatic immune response in vivo

丙型肝炎病毒非结构蛋白NS5A在体内会损害肝脏的先天性和适应性免疫反应。

Kriegs, Malte; Bürckstümmer, Tilmann; Himmelsbach, Kyoshi; Bruns, Michael; Frelin, Lars; Ahlén, Gustaf; Sällberg, Matti; Hildt, Eberhard